UBS Maintains Neutral Rating For Bristol-Myers, $27 Price Target (BMY)

UBS Maintains Neutral Rating For Bristol-Myers, $27 Price Target (BMY)

Comtex Smartrend - 7 hours ago

By Chip Brian, SmarTrend Analytics Team 2/23/2010- UBS analysts are maintaining a "neutral" rating for Bristol-Myers (NYSE:BMY) and price target of $27. The company's application for its treatment ...

http://digg.com/u1O8fv